BC053749 Activators
BC053749 Activators encompass a diverse array of chemical compounds that indirectly enhance the functional activity of BC053749 through a variety of signaling mechanisms. Forskolin and Isoproterenol, both acting to raise intracellular cAMP levels, contribute to the activation of PKA, which may phosphorylate BC053749 or affect its activity through other cAMP-dependent mechanisms. PMA activates PKC, which has the potential to directly phosphorylate BC053749 or alter its function by modulating related signaling pathways. Similarly, the calcium ionophores Ionomycin and A23187 increase intracellular calcium concentrations, which can activate calcium-dependent kinases that may subsequently enhance BC053749 activity. Sphingosine-1-phosphate activates downstream kinasessuch as Akt, which can lead to the phosphorylation of BC053749 or the modulation of its associated pathways, while EGCG, by inhibiting tyrosine kinases, may allow for increased BC053749 activity by reducing competitive signaling interference.
Furthermore, the PI3K inhibitor LY294002 may lead to compensatory signaling changes that enhance BC053749 activity, and the MEK inhibitor U0126 can influence MAPK pathway signaling, potentially leading to an indirect enhancement of BC053749. Anisomycin, as a JNK activator, can modulate MAPK signaling pathways, potentially leading to the upregulated activity of BC053749. SB203580, by inhibiting p38 MAPK, may also shift signaling in favor of enhancing BC053749 activity. Lastly, Thapsigargin, by disrupting calcium homeostasis, can activate calcium-dependent signaling pathways that could indirectly lead to the enhanced activity of BC053749. Collectively, these activators work through distinct yet interconnected pathways, converging on the enhancement of BC053749's functional role within the cell without directly increasing its expression or requiring direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol (DAG) analog that activates protein kinase C (PKC). PKC can phosphorylate BC053749 directly or modulate the signaling pathways that BC053749 is involved in, thus enhancing its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calcium-dependent protein kinases, which may phosphorylate BC053749 or modulate its function indirectly through calcium-dependent signaling pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate (S1P) engages S1P receptors, which can activate downstream kinases such as Akt. Activation of this pathway can enhance the activity of BC053749 through post-translational modifications or by influencing signaling cascades that BC053749 is part of. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a tyrosine kinase inhibitor that may reduce competitive signaling, thus potentiating BC053749 activity by allowing it to become more prominent in pathways where tyrosine kinase activity is normally dominant. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that alters the PI3K/Akt pathway. By inhibiting PI3K, downstream signaling including pathways involving BC053749 may be affected, potentially leading to enhanced activity of BC053749 through a compensatory mechanism. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore that, like Ionomycin, raises intracellular calcium levels, potentially leading to the activation of calcium-dependent signaling pathways that enhance the activity of BC053749. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that can shift the balance of MAPK pathway signaling, which may indirectly enhance the activity of BC053749 by affecting related pathways or proteins that interact with BC053749. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator that can influence MAPK pathway signaling. The activation of JNK could lead to the enhancement of BC053749 activity by modulating the signaling pathways or molecular interactions that BC053749 is involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can alter signaling dynamics within the MAPK pathway, potentially leading to enhanced BC053749 activity via indirect effects on proteins and pathways that interact with or regulate BC053749. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium. This can trigger calcium-dependent signaling pathways that may indirectly enhance the activity of BC053749. | ||||||